Compass Therapeutics prices $125M public offering of 35.7M shares at $3.50; uplists to Nasdaq

Compass Therapeutics, Inc.

Underwritten public offering of 35,715,000 shares at $3.50/share; underwriters have 30-day option for additional 5,357,250 shares.
Gross proceeds ~$125M; net proceeds after discounts and expenses ~$117.3M.
Common stock to trade on Nasdaq Capital Market under ticker CMPX starting November 2, 2021.
SVB Leerink is book-running manager; Raymond James, Wedbush, H.C. Wainwright as passive book-runners.
Net proceeds to fund ongoing operations including clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.